The US Court of Appeals for the Federal Circuit determined that the limitation “a pH of 13 or higher” could not be construed using the asserted patents’ intrinsic evidence and therefore remanded to the district court with...more
The US Court of Appeals for the Federal Circuit ordered that the only Orange Book patent asserted in a lawsuit must be delisted since its claims were directed to the computer-implemented distribution system and not a method...more
3/9/2023
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Claim Construction ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Markman Hearing ,
Method of Manufacture ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
REMS